Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...

AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax,...